Is Coral Labs. overvalued or undervalued?

As of 30 October 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued. Key ratios include a PE Ratio of 9.83, an EV to EBITDA of 4.40, and a Price to Book Value of 0.90, all of which suggest that the stock is trading at a discount compared to its peers.
In comparison to its industry, Coral Labs' PE Ratio is significantly lower than that of Sun Pharma, which stands at 35.63, and Divi's Lab at 76.52, both categorized as expensive. Additionally, while Coral Labs has a PEG Ratio of 0.00, indicating potential growth at a low price, peers like Cipla and Dr. Reddy's Labs, both rated attractive, have PEG Ratios of 1.28 and 2.15, respectively. Despite recent underperformance against the Sensex over the past year, Coral Labs' strong ratios suggest it remains a compelling investment opportunity.